Introducing KEYNOTE-B61 in Non–Clear Cell RCC

Now Viewing

EP: 1.Introducing KEYNOTE-B61 in Non–Clear Cell RCC

EP: 2.Challenges in Treating Non–Clear Cell RCC

Introducing KEYNOTE-B61 in Non–Clear Cell RCC

This segment introduces a Cancer Network Between the Lines Journal Club discussion focused on the KEYNOTE-B61 study examining pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell RCC. The abstract being discussed presents 3-year follow-up data from this phase 2 clinical trial, which was presented at the 2025 Kidney Cancer Research Summit in Boston, Massachusetts. The discussion, featuring 2 expert clinicians specializing in kidney cancer treatment and research, is moderated by a genitourinary oncologist from the Cleveland Clinic, setting the stage for an in-depth analysis of this important therapeutic combination.

The moderator is joined by a medical oncologist from Johns Hopkins Medicine who focuses specifically on the care and research of patients with kidney cancer. Both physicians bring extensive clinical expertise to the discussion, providing a foundation for analyzing the real-world implications of the KEYNOTE-B61 study results and their potential impact on patient care.

The format of this journal club session is structured to provide comprehensive coverage of the topic, beginning with a general overview of non–clear cell RCC as a disease entity. The discussion will then transition into a specific analysis of the phase 2 KEYNOTE-B61 study, including a detailed review of the clinical data and outcomes. The session concludes with expert commentary on how these findings can be integrated into current clinical practice, considering the broader landscape of available treatment options for patients with advanced non–clear cell RCC.